Quintiles, dabl Team to Advance Cardiovascular Safety Assessment
Media RelationsJohn Kelly, +353 1 2780247orMedia RelationsMari Mansfield, +1 919 998 2639orGreg Connors, +1 919 998 2000Investor Relations
dabl Limited, a provider of centralized ambulatory blood pressure measurement (ABPM) services, and Quintiles, the world’s leading global biopharmaceutical services company, today announced a strategic alliance that significantly enhances Quintiles’ suite of offerings in cardiovascular safety assessment.
Through the alliance, Quintiles’ customers worldwide will have access to dabl’s round-the-clock ABPM services to enhance the safety and efficacy of global clinical trials across the entire trial lifecycle.
“dabl’s scientific leadership and data management techniques are setting new industry standards and complement Quintiles’ pioneering cardiac safety solutions,” said Dr. Deepa Desai, Executive Director, Cardiac Safety Services, Quintiles. “Together we can improve understanding of drug-induced blood pressure responses and help our customers improve trial participant safety, manage risk, and improve efficiency – all vital to meet the challenges of .”
The U.S. FDA and other regulatory agencies are requiring assessment of 24-hour blood pressure profiles for blood pressure-lowering drugs; there is also increased focus on how non-cardiovascular drugs affect blood pressure. The Web-based dabl ABPM system automatically checks data in accordance with the study protocol; generates alerts about safety and enrollment issues; and provides real-time access to clinical data and progress reports.
Professor Eoin O’Brien, Medical Director of dabl, said: “Accuracy of circadian measurement, speed and excellence in interpreting data have never been more important in the clinical trial process. Biopharma companies will be able to make faster and more confident decisions about the cardiovascular effects of their compounds with the combination of Quintiles’ therapeutic expertise and dabl’s proprietary technology and excellence in providing haemodynamic profiles.”
W.J. “Bill” Rickard, Chief Executive Officer of dabl, said: “We welcome this alliance with Quintiles. It’s another milestone in our development, particularly in our rapidly growing Global Clinical Trial Division.”
is the world’s leading provider of biopharmaceutical services. With a network of more than 27,000 professionals working in more than 80 countries, we have helped develop or commercialize all of the top 50 best selling drugs on the market. With extensive therapeutic, scientific and analytics expertise, we help biopharmaceutical and health sciences customers navigate the increasingly complex landscape with more predictability to enable better outcomes.
Professor Eoin O’Brien and W.J. Rickard founded dabl in Dublin, Ireland in 2000 to improve the application of 24-hour ABPM in clinical research and practice. dabl’s scientific leaders have been responsible for many ABPM research breakthroughs and have authored many of the current hypertensive guidelines and standards. In 1988, Prof. O’Brien reported the association between increased night-time blood pressure and adverse cardiovascular outcomes. Today, dabl’s services cover the entire ABPM project life cycle including study design & protocol development, consulting, medical writing, project management and logistics, data management and bio-statistics. For more information, please visit .
Click to subscribe to Mobile Alerts for Quintiles.